Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in a fireside chat at the Stifel 2024 Healthcare Conference being held in New York, NY, November 18-19, 2024.
波士顿，2024年11月12日（GLOBE NEWSWIRE）——Cue Biopharma, Inc.（纳斯达克股票代码：CUE）是一家处于临床阶段的生物制药公司，正在开发一种新的治疗生物制剂，用于选择性地参与和调节用于治疗癌症和自身免疫性疾病的疾病特异性T细胞。该公司今天宣布，它将参加在新举行的Stifel 2024医疗保健会议的炉边谈话纽约州约克，2024年11月18日至19日。
During the fireside chat, Cue Biopharma will highlight current updates in its oncology and autoimmune disease programs. This includes discussing recent data highlights from its Phase 1 clinical programs, CUE-101 and CUE-102, presented at the recent Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024).
在炉边谈话中，Cue Biopharma将重点介绍其肿瘤学和自身免疫性疾病项目的最新动态。这包括讨论其第一阶段临床项目 CUE-101 和 CUE-102 的最新数据亮点，这些数据在最近的癌症免疫疗法学会第39届年会（SITC 2024）上发布。
Presentation Details
Date and Time: Tuesday, November 19 from 1:15 p.m. EST – 1:45 p.m. EST
Webcast Link:
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
演示详情
日期和时间：美国东部时间11月19日星期二下午 1:15 至美国东部标准时间下午 1:45
网络直播链接：
主持人：Daniel Passeri万.Sc.，法学博士，Cue Biopharma首席执行官
A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company's website at . The webcast will be archived for 30 days.
公司网站 “投资者与媒体” 部分的 “活动” 页面上将提供炉边谈话的直播和存档网络直播，网址为。网络直播将存档30天。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
关于 Cue Biopharma
临床阶段的生物制药公司Cue Biopharma正在开发一种新型的可注射生物制剂，用于选择性地直接参与和调节患者体内的疾病特异性T细胞。该公司的专有平台Immuno-Stat（T细胞的选择性靶向和改变）和生物制剂旨在通过选择性调节疾病特异性T细胞来利用人体内在免疫系统的治疗潜力，而不会受到广泛的全身免疫调节的不利影响。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
我们总部位于马萨诸塞州波士顿，由经验丰富的管理团队和独立董事会领导，他们在免疫学和免疫肿瘤学以及蛋白生物制剂的设计和临床开发方面拥有深厚的专业知识。
For more information please visit and follow us on X and LinkedIn.
欲了解更多信息，请访问并在 X 和 LinkedIn 上关注我们。
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投资者联系人
玛丽·坎皮内尔
企业传播高级董事
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒体联系人
乔纳森·帕帕斯
LifeSci
jpappas@lifescicomms.com